Lipocine Inc.

Lipocine Inc.

Lipocine Inc. was incorporated in 2014 as a Delaware corporation, building on research into oral drug-delivery systems. The company's wealth origin is corporate, supported by public equity markets via its Nasdaq listing under ticker LPCN. Founders and early leadership included Dr. Mahesh V. Patel, a pharmaceutical scientist with prior experience at Alkermes and Schering-Plough. The company operates as a development-stage biopharmaceutical firm, focusing on asset classes that include clinical-stage drug candidates and intellectual property. Its lead pipeline candidate is LPCN 1021, which is in clinical trials for alcohol use disorder, as of public filings in 2023. Lipocine also has preclinical stage assets targeting other central nervous system indications. The firm's primary geography is the United States, with no disclosed international operations. Lipocine is a small organization with limited publicly disclosed headcount. As of its 2023 annual report, the company reported no revenue and relied on equity and debt financing for operations. A notable recent event was the receipt of U.S. patent allowances for its OralLine technology in 2023 (per the company's press release). The firm does not operate adjacent philanthropic or investment vehicles. The company's structural differentiator is its focus on a single drug-delivery platform applied to central nervous system disorders, differentiating it from larger diversified pharma. Its governance includes a board of directors responsible for strategic decisions, with no disclosed succession plans beyond standard corporate continuity.